PCYC : Summary for Pharmacyclics, Inc. - Yahoo Finance

U.S. Markets closed

Pharmacyclics, Inc. (PCYC)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
257.100.00 (0.00%)
At close: 2:59PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close257.10
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals3 days ago

    Here’s where a Pinellas billionaire and top donor to Church of Scientology is putting his investment dollars

    Robert Duggan, one of the most influential executives in the biopharmaceutical field, has bought a 15.4 percent stake in Pulse Biosciences Inc., a Burlingame, California medical technology company. Duggan, who relocated to the Tampa Bay area after selling biotech firm Pharmacyclics to AbbVie in May 2015 for $21 billion, controls nearly 2.2 million shares of Pulse Biosciences (PLSE), with most of the stock purchased between Dec. 7 and Feb. 9, a Feb. 21 filing with the U.S. Securities and Exchange Commission said. Duggan has a net worth of $2.6 billion, according to Forbes, which included him on the 2016 list of the 400 wealthiest people in the United States.

  • American City Business Journals12 days ago

    These drug and medical device companies made the most payments to Chicago hospitals

    Drug company Pharmacyclics made the highest amount of non-research payments out of the more than $9 million in payments received by 25 Chicago-area doctors in 2015. Sunnyvale, California-based Pharmacyclics, ...

  • Why June Could Be a Big Month for AbbVie Investors
    Motley Fool9 months ago

    Why June Could Be a Big Month for AbbVie Investors

    A key presentation at ASCO next month for Stemcentrix's Rova-T could cause shares to pop.